The disclosure relates to 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine derivatives represented by formula (I), wherein the variables are as defined in the specification. These phenyl-pyrimidine derivatives are suitable as P2Y12 adenosine 5'-diphosphate (ADP) receptor antagonists and are used in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.
